Hence, we concluded that UBE2C may be a critical factor for predicting the prognosis of ccRCC patients and that the detected expression level of UBE2C from PBMC may contribute to predicting tumor progression and aid immunotherapy in ccRCC. This evidence concerns the gene UBE2C and nonpapillary renal cell carcinoma.